Newomics Inc. announces its collaboration with Bruker Corporation on high-throughput bioanalysis

Written by Amy White
Collaborations and mergers MS (LC–MS/MS, HRMS, IMS) News

Newomics Inc. (CA, USA) has announced collaborations with Bruker Corporation (MA, USA), a company with differentiated high-value life science research and diagnostics solutions, on a novel LC–MS platform for drug discovery in the pharma and biopharma industries.

Daojing Wang, Founder and CEO of Newomics Inc., stated:

“We are excited to expand our successful collaborations with Bruker…Our M3 emitter is the first commercial multinozzle emitter for mass spectrometry. The new microflow-nanospray electrospray ionization source directly addresses several key pain points in mass spectrometry analysis of native proteins, protein complexes, and oligonucleotides, and opens up new opportunities for biopharmaceutical and clinical research and development.”

Newomics Inc., a biotechnology company commercializing mass spectrometry solutions for molecular detection, and Bruker Corporation have both agreed upon co-marketing Newomics’s microflow-nanospray electrospray ionization (MnESI) product line with Bruker’s maxis II and timsTOF Pro 2 mass spectrometers.

You may also be interested in:

Michael Greig, Director of Pharma/Biopharma Americas at Bruker Corporation, commented:

“This co-marketing agreement is built upon close collaborations between our R&D teams over the last several years. We look forward to working with Newomics to create workflows using MnESI products on Bruker mass spectrometers for biologics and native mass spec applications.”

The joint MnESI–MS platform will offer unrivaled isotopic fidelity, sensitivity, robustness, and reproducibility for high-throughput analysis of small volumes of biological samples.

Source: Newomics Inc. news release www.newomics.com/news/newomics-and-bruker-collaboration/